Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by OBI Pharma Inc.
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors
September 02, 2025
From
OBI Pharma Inc.
Via
GlobeNewswire
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
June 06, 2025
From
OBI Pharma Inc.
Via
GlobeNewswire
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC
April 30, 2025
From
OBI Pharma Inc.
Via
GlobeNewswire
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science
April 22, 2025
From
OBI Pharma Inc.
Via
GlobeNewswire
OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
March 12, 2025
From
OBI Pharma Inc.
Via
GlobeNewswire
OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production
December 23, 2024
From
OBI Pharma Inc.
Via
GlobeNewswire
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy
June 12, 2024
From
OBI Pharma Inc.
Via
GlobeNewswire
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
March 18, 2024
From
OBI Pharma Inc.
Via
GlobeNewswire
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
January 03, 2024
From
OBI Pharma Inc.
Via
GlobeNewswire
OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer
June 02, 2023
From
OBI Pharma Inc.
Via
GlobeNewswire
OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy
April 10, 2023
From
OBI Pharma Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.